Sign up
Log in
MARKET
CLRB
CLRB
Cellectar Biosciences Inc
NASDAQ
2.290
-0.075
-3.17%
After Hours: 2.280 -0.01 -0.44% 19:47 07/26 EDT
OPEN
2.380
PREV CLOSE
2.365
HIGH
2.460
LOW
2.240
VOLUME
566.86K
TURNOVER
0
52 WEEK HIGH
4.450
52 WEEK LOW
1.560
MARKET CAP
82.09M
P/E (TTM)
-0.7214
1D
5D
1M
3M
1Y
5Y
1D
Buy Rating Affirmed for Cellectar Biosciences on Strong Clinical Results and Improved Financial Outlook
TipRanks · 2d ago
Cellectar: WM Treatment Data Leads To A Few Regulatory Milestones
Cellectar Biosciences, Inc. Reported positive results from its pivotal phase 2 study, using iopofosine for the treatment of patients with refractory Waldenstrom's macroglobulinemia. The company is expected to file a New Drug Application in Q4 of 2024. The potential to have therapy given Priority Review. The possible market for relapsed/refractory WM patients stands at a $1.05 billion.
Seeking Alpha · 3d ago
Gold Moves Higher; Coca-Cola Increases FY24 Forecast
U.S. Stocks traded slightly higher toward the end of trading on Tuesday. The Dow Jones gained more than 50 points and the NASDAQ rose 0.20%. Coca-Cola Company reported better-than-expected second-quarter results and raised its guidance. Azitra, Inc. Shares shot up 326% after being granted a patent for treatment of atopic dermatitis.
Benzinga · 3d ago
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Comcast Corporation shares fell 6.1% to $37.12 on Tuesday. The company reported worse-than-expected second-quarter sales results. Azitra, Inc. Shares jumped 529% after company received patent for treatment of atopic dermatitis. Other stocks moving in the mid-day session include GE Aerospace and Owens & Minor.
Benzinga · 3d ago
Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Cellectar Biosciences Inc. Reports results from its CLOVER WaM pivotal study. The study evaluated iopofosine I 131 for relapsed/refractory Waldenstrom’s macroglobulinemia. The company plans to file an FDA marketing application in the fourth quarter of 2024.
Benzinga · 3d ago
Cellectar falls after updating pivotal data for lead asset
Cellectar falls after updating pivotal data for lead asset iopofosine I 131 in rare type of blood cancer. Cellectar Biosciences lost 14% premarket Tuesday after updating results from its CLOVER WaM pivotal study. The company plans to submit a marketing application for the candidate in Q4 2024.
Seeking Alpha · 3d ago
Cellectar Reports Promising iopofosine Study Results
TipRanks · 3d ago
Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
Benzinga · 3d ago
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstrom’s macroglobulinemia (WM).
Webull offers Cellectar Biosciences Inc stock information, including NASDAQ: CLRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading CLRB stock methods without spending real money on the virtual paper trading platform.